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Abstract
The results of analysis of shotgun proteomics mass spectrometry data can be greatly affected by 
the selection of the reference protein sequence database against which the spectra are matched. For 
many species there are multiple sources from which somewhat different sequence sets can be 
obtained. This can lead to confusion about which database is best in which circumstances – a 
problem especially acute in human sample analysis. All sequence databases are genome-based, 
with sequences for the predicted gene and their protein translation products compiled. Our goal is 
to create a set of primary sequence databases that comprise the union of sequences from many of 
the different available sources and make the result easily available to the community. We have 
compiled a set of four sequence databases of varying sizes, from a small database consisting of 
only the ~20,000 primary isoforms plus contaminants to a very large database that includes almost 
all non-redundant protein sequences from several sources. This set of tiered, increasingly complete 
human protein sequence databases suitable for mass spectrometry proteomics sequence database 
searching is called the Tiered Human Integrated Search Proteome set. In order to evaluate the 
utility of these databases, we have analyzed two different data sets, one from the HeLa cell line 
and the other from normal human liver tissue, with each of the four tiers of database complexity. 
The result is that approximately 0.8%, 1.1%, and 1.5% additional peptides can be identified for 
Tiers 2, 3, and 4, respectively, as compared with the Tier 1 database, at substantially increasing 
computational cost. This increase in computational cost may be worth bearing if the identification 
of sequence variants or the discovery of sequences that are not present in the reviewed knowledge 
base entries is an important goal of the study. We find that it is useful to search a data set against a 
simpler database, and then check the uniqueness of the discovered peptides against a more 
complex database. We have set up an automated system that downloads all the source databases on 
the first of each month and automatically generates a new set of search databases and makes them 
available for download at http://www.peptideatlas.org/thisp/.
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Introduction
Mass spectrometry-based proteomics enables high-throughput identification and 
quantification of proteins in biological samples, with improved technology realizing steady 
increases in comprehensiveness of sample characterization over the past few decades. 
Targeted techniques (e.g., selected reaction monitoring (SRM)) are increasingly being used 
for quantification of subsets of proteins, but data-dependent acquisition (DDA) peptide ion 
collision induced fragment tandem mass spectrometry (MS/MS), also known as shotgun 
proteomics, remains the most widely used technique in the proteomic community. In the 
shotgun workflow, the instrument acquires survey scans to determine the mass and charge 
(m/z) of all precursor ions entering at each time point, and then proceeds to isolate one or 
more of these precursor ions in turn, fragmenting each, and acquiring a spectrum of the 
resulting fragment ions.
The acquisition of many thousands of MS/MS spectra is then followed by extensive 
computational analysis that aims to interpret these MS/MS spectra to determine which 
peptide ions yielded them, followed by inference of the proteins from which the peptides 
were derived1. Interpretation of the MS/MS spectra is achieved via one of three main 
techniques: sequence database searching, spectral library searching, and de novo spectrum 
interpretation, or some combination of these. The de novo technique is quite dependent on 
high quality spectra and manual intervention, and therefore typically used only when 
reference databases of possible matches are not available. Spectral library searching relies on 
a high quality library of previously identified spectra from past work, and has only been 
used significantly by a few laboratories, in part due to the paucity of comprehensive spectral 
libraries. This leaves sequence database searching as the most widely used technique by far. 
Sequence database search engines2, of which there are dozens, rely on a list of protein 
sequences from which to select plausible peptide ion candidates to compare with the input 
spectra in order to select the best match.
The selection of the sequence database to use for interpretation of shotgun data is therefore 
crucial to the outcome of the analysis. Most importantly, the correct identification of an 
MS/MS spectrum requires that the peptide from which it was derived be present in the 
sequence database. Therefore, comprehensive databases are important for a high quality 
analysis of a dataset. Yet, very large databases can be detrimental to an analysis because as 
the database size grows, so does the search space of all peptides that a search engine must 
consider, thereby increasing the background of incorrect matches and reducing the overall 
sensitivity of the analysis. For comprehensive database search analysis, an optimal database 
would contain all of the proteins present in an analyzed sample (and where the sample 
protein sequences and the database entry sequences match precisely) without an excessive 
number of proteins not present. Since the set of proteins present in a sample is rarely known 
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exactly, it is customary to use a conveniently obtained and reasonably complete entire 
proteome for the species under analysis.
Although for some species there is rather little choice in the selection of reference protein 
sequence database (usually UniProtKB), for human samples there is a bewildering array of 
choices for which database to use. Several of the major bioinformatics institutes release one 
or more human protein databases, including the major ones from Ensembl3, RefSeq4, 
UniProtKB5, and neXtProt6. Historically, the International Protein Index (IPI)7, an amalgam 
of multiple sources, was an extremely comprehensive and widely used database, but is no 
longer produced. Even these individual sources of sequence can come in multiple versions. 
UniProtKB contains ~20,000 proteins in its reviewed “canonical” set, another ~22,000 in the 
“varsplic” alternative splice isoforms set, ~67,000 in its “complete proteome” set, and over 
140,000 sequences in the full set of all human UniProtKB sequences including TrEMBL. It 
is always important to specify the version and date of the reference database so as to provide 
an audit trail of the sequence analysis performed.
Each of these many sequence databases is assembled with clear methods but with differing 
goals. Yet none of them is specifically geared for proteomics sequence database searching. 
This has motivated past works which created derivative sequence databases that were 
optimized for proteomics database search. The MScDB resource was devised as a technique 
to reduce redundancy in a sequence database with only small loss of completeness in order 
to decrease search times8. The msIPI resource was devised as an enhancement to the IPI 
database to make it more amenable to proteomics sequence searching9. Yet, these efforts are 
not kept current as new reference proteomes are made available and are thus rarely used.
The Human Proteome Project10, 11 has begun an international effort to vastly improve our 
understanding of the full complement of proteins responsible for human development, 
health, and disease, including post-translational modifications, sequence variants, and splice 
variants. A key aspect of such an effort is to understand and leverage the full set of protein 
sequences that could be produced with the ultimate goal to understand the function of each 
protein..
When one examines the recent shotgun proteomics literature, it is apparent that nearly all 
databases that could be used are being used by the community. In many cases, the database 
used may merely be the most expedient and is often rather stale. It is certain that there is not 
a single database that is most appropriate for all applications. With the variety of options 
available, how can one know which is the most appropriate human proteomics search 
database and is there a database that includes all of the sequences relevant to a study?
Here we explore this question by collecting most of the available sequence databases, 
creating a tiered set of merged databases, and comparing the performance of these merged 
databases relative to each other. We have created four different tiers of complexity of 
databases. The scope and content of each of these tiers is well defined and allows 
researchers to decide which tier of complexity is most appropriate for their analysis goals. 
We assess how they compare in terms of overall comprehensiveness, search speed, and 
search results. In the sections below we first introduce the set of potential sequence 
Deutsch et al. Page 3
J Proteome Res. Author manuscript; available in PMC 2016 November 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
databases of various sizes from various sources, compare their relative attributes, describe 
the newly created merged databases, introduce a test methodology, compare the search 
results of our test set against these databases, and conclude with their availability. This tiered 
scheme is intended for routine shotgun analyses as well as for special analysis of claims of 
identification of missing proteins or novel translation products11, 12 covered by the HPP 
Guidelines for Mass Spectrometry Interpretation13.
Methods
Assembling source protein sequence databases
We first assemble an extensive set of human protein sequence databases, including one or 
more sets from Ensembl, RefSeq, UniProtKB, and neXtProt, as well as sets of historical 
interest such as the final release14 of the International Protein Index (IPI)7. A complete list 
of the sequence databases considered is listed in Table 1, along with attributes of each of the 
databases. The version listed is either a specific tag, the release date given by the provider, or 
the download date for databases acquired without a specific version tag. All databases are 
the most recent available on 2016-05-01. These databases are primarily in the FASTA 
format, although we also use the UniProtKB DAT format and neXtProt XML format to 
extract variant information. The number of proteins in each database is a simple count of 
entries, and the number of distinct proteins is the number of entries where sequence-exact 
duplicates are only counted once. The number of distinct peptides (7–50) is a tally of all 
distinct peptides between 7 and 50 amino acids inclusive after in silico digestion with trypsin 
with no missed cleavages (K or R followed by P is excluded as a cleavage site); peptides that 
are otherwise identical except for an I/L substitution are not counted twice. This column is 
intended to provide a sense of the redundancy of each database, and the exact peptide length 
range is not very important. We select the range 7–50 amino acids as this encompasses 
99.5% of all peptides in PeptideAtlas, and thus seems like a reasonable range; selection of a 
slightly different range would change all the values in this column proportionally. Finally, 
the last column provides a short description of each database. The complete URL used to 
download each of these databases is provided at the stable URL for the results and 
derivatives of this work at http://www.peptideatlas.org/thisp/.
We briefly describe the databases that we acquire from external sources as follows: The 
“Swiss-Prot canonical” database consists of the 20,193 manually reviewed human entries 
from UniProtKB/Swiss-Prot. The “Swiss-Prot canonical + varsplic” database contains all the 
Swiss-Prot canonical entries as just described plus an additional set of “varsplic” alternative 
splice isoforms associated with the canonical sequences. The “neXtProt” database is derived 
from the “Swiss-Prot canonical + varsplic” database, sharing similar entries and accession 
numbers, but with many more annotations and links. The neXtProt project puts extra effort 
and focus into enhancing annotations for the human species exclusively, while UniProtKB/
Swiss-Prot handles all species. Approximately 130 entries in UniProtKB/Swiss-Prot are 
excluded from neXtProt as they are considered an unrepresentative subset of 
immunoglobulin sequences. For the 2016-02 release of neXtProt used here, there are 20,055 
canonical entries, i.e. excluding the additional “varsplic” alternative splice isoforms.
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The “UniProtKB Complete Proteome” database includes all UniProtKB/Swiss-Prot 
canonical sequences and adds sequences from the UniProtKB/TrEMBL set that have an 
identical corresponding sequence entry in Ensembl. These are often alternative splice 
isoform sequences and other variants that are not yet reviewed. The “NCBI RefSeq NP” 
database contains all the sequences from Reference Sequence resource from NCBI that have 
been reviewed by a curator. The “NCBI RefSeq XP” database contains all unreviewed 
sequences. The “Ensembl” database contains the complete list of gene products as derived 
from an automated process with gene to transcript to protein provenance. The “International 
Protein Index (IPI)” database was the result of an automated system that created a non-
redundant set of protein sequences from most of the resources in Table 1, but is now 
discontinued. The “IMGT” database15 is a resource that collates a set of known human 
immunoglobulin (Ig) sequences, although it does not include all of the Ig sequences present 
in UniProtKB/Swiss-Prot (but dropped in neXtProt). The final source database is the 
“cRAP” database, a “common Repository of Adventitious Proteins” maintained by the 
Global Proteome Machine (GPM)16 resource.
Creating tiered search databases with automated updates
Based on these downloaded source databases, we create a tiered series of databases starting 
with neXtProt and UniProtKB, yet augmented to include additional sequence that may be 
detected in shotgun proteomics experiments. We term these new databases the “Tiered 
Human Integrated Search Proteome” (THISP) databases.
First we assemble a set of individual components based on the sources listed in Table 1. 
These components are listed in Table 2. Many of the Table 2 components are exactly as 
listed in Table 1. However, a few variances are described as follows. The “SPnotnP” 
component is a group of proteins present in UniProtKB/Swiss-Prot but intentionally 
excluded from neXtProt, as they are primarily a set of immunoglobulin (Ig) proteins that 
were added in the 1970s and are now deemed an obsolete, unrepresentative subset of Igs 
(Amos Bairoch (SIB), private communication). However, we include them here as most 
contain peptides that are detected in shotgun proteomics experiments. The “Nh-cRAP” 
component is the subset of non-human proteins in the cRAP database; the human ones are 
dropped because they are already present in the “nP20k” set. The “Microbe” component is a 
set of proteins from viruses and other microbes that may be detectable in human samples 
(including cell lines), primarily from Chernobrovkin and Zubarev17. Virus, bacteriophage, 
and bacterial sequences are likely to become more important as microbiome analyses are 
integrated with proteomics studies of human samples. The “IPIorphan” set contains a small 
subset of proteins (currently 11) from the deprecated final release of the IPI database that 
appear to have high confidence hits in past and current Human PeptideAtlas builds that do 
not map readily elsewhere. Some may be false positives, but most appear to be alternative 
splice isoforms not yet included in the “varsplic” set, and have peptides that uniquely 
identify them. It is intended that this set will eventually be removed as these individual cases 
are evaluated and the identified sequences integrated into neXtProt. These sequences are 
available for each release at the web site in the downloadable components file.
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The “Contribs” component represents a set of proteins of interest from one or more of the 
genome annotation curators such as from the HAVANA Group18, or otherwise contributed to 
PeptideAtlas as under consideration for translation. These sequences are either reported in 
the literature as coding or there is some suspicion that they might be coding and have thus 
been referred to PeptideAtlas for further consideration if there is high quality peptide 
evidence to support them. The “RSDiffNP” component is the set of RefSeq NP (reviewed) 
sequences that do not have an exact sequence counterpart in neXtProt or UniProtKB. 
Similarly, the “RSDiffXP” component is the set of RefSeq XP (unreviewed) sequences that 
do not have an exact sequence counterpart in neXtProt or UniProtKB.
Although we had initially planned to include an increasing set of single amino acid variants 
(SAAVs) in the databases, we discovered that searching for hundreds of thousands of 
SAAVs resulted in erroneous identification of more than one thousand of them in these 
datasets. The erroneous identifications yielded by our searches could be better explained by 
mass modifications such as deamidation and oxidation, rather than true SAAVs. These errors 
were not modeled well by the decoys we had generated. For this reason, we do not include 
SAAVs in the database, and recommend that any search for hundreds of thousands of 
SAAVs must be accompanied by special statistical approaches to control these sorts of 
errors. This problem will be explored further in a subsequent work.
We do, however, provide the PeptideAtlas mapping database, which does contain the 
expanded peptide sequences for a subset of SAAVs found in neXtProt. These expanded 
peptide sequences contain SAAVs flanked on each side by up to 30 amino acids so that they 
may be readily detected with standard search strategies. The PeptideAtlas mapping database 
contains the “SAAVnPnotCOS” component, which represents all the SAAVs that are listed 
in neXtProt, except for SAAVs that are exclusively annotated as originating from the 
Catalog of Somatic Mutations in Cancer (COSMIC)19, since this presents a very large list of 
SAAVs that may be less likely to be detected in most non-disease tissue and biofluid 
samples. The “SAAVnPall” component includes all SAAVs contained in neXtProt. This list 
is quite large, with over 1.7 million SAAVs as of the 2016-02 release, making it very 
computationally expensive for searching and perhaps not even useful for the purposes of 
mapping.
Next, we merge these components in several different combinations to create the THISP Tier 
1 – 4 databases as shown in Table 3. Tier 1 encodes the simplest database, essentially with 
just the ~20,000 primary isoforms plus contaminants. Tier 2 adds all neXtProt varsplic 
entries, and immunoglobulin variable region sequences from UniProtKB/Swiss-Prot and 
IMGT. Tier 3 adds UniProtKB “Complete Proteome” and additional sequences from other 
small sources as listed. Finally, Tier 4 is a “kitchen sink” database that includes nearly all 
distinct sequences from all sources. Also listed in Table 3 is the PeptideAtlas mapping 
database, as further discussed below.
The tiered databases we created are available in the several different forms described at 
http://www.peptideatlas.org/thisp/. The exact forms that we use in the below assessment will 
remain available. But, also, in order to prevent the decay of this resource, we have deployed 
an automated system that will regenerate the database in its various forms on the first of 
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every month and post it to the same web site for download. This will ensure that this set of 
THISP databases will remain fresh and usable by the community in the future. Should the 
assembly procedure be altered in the future, the change notes will be posted at the site as 
well. The software used to build these is also available at the site so that users may build the 
THISP databases on their own schedule or alter it to suit their needs.
For each combined database we generate an equal sized set of decoy proteins and interleave 
(i.e. put each decoy immediate after its target entry) these with the target sequences 
(interleaving versus appending can have an effect for some workflows). The decoy proteins 
are created by starting with each target protein and preserving the location of each initiating 
M, K, R, and P if it immediately follows K/R. All other amino acids between each boundary 
are scrambled to a different order, except in cases where a different order is not possible. 
This has the effect of retaining the mass distribution of peptides within the database. During 
the process, each tryptic peptide and its scrambled version is stored in a hash; if the same 
tryptic peptide is encountered a subsequent time, the scrambled value from the hash is used 
instead of generating a new scramble. This has the effect of preserving the level of 
redundancy in the database. The hash is persisted and reloaded for each database, so each 
tryptic peptide will have a unique scrambled equivalent globally. All this is performed with 
the TPP tool decoyDatabase.pl. Although this procedure is trypsin-centric, the decoys are 
still suitable for other protease specificities, although the mass distribution of peptides for 
other proteases will be slightly altered.
Sequence searching example datasets with tiered databases
In order to compare the relative merits of these databases for the purpose of database 
searching, we selected two test datasets, searched them against all of the databases, and 
compared the results. The first dataset is from a HeLa whole cell lysate which was separated 
into 48 fractions and analyzed through an LTQ Orbitrap Velos using HCD and high mass 
resolution at both the MS1 and MS2 levels as first published in Nagaraj et al.20. The raw 
data files for this experiment can be found in their original form in the PeptideAtlas raw data 
repository at http://www.peptideatlas.org/repository/ under accession number PAe003653.
The second dataset is a normal human liver tissue dataset from Wilhelm et al.21. The tissue 
sample was separated via a 4–12% NuPAGE gel and cut into 24 slices prior to in-gel 
digestion and analyzed with an LTQ Orbitrap Elite using HCD and high mass resolution at 
both the MS1 and MS2 levels. It can be found in its original form at http://
proteomecentral.proteomexchange.org/dataset/PXD00865.
We processed each of these datasets with two different search engines, Comet22 version 
2015.02 rev.0 and X!Tandem23 version 2013.06.15.1 with the hrk-score plugin, which is a 
special modification of the original k-score24 for high-resolution MS2 spectra. We do not 
intend to compare the relative merits of the different search engines, but rather combine the 
results of the two searches into a single, better result25. Each search was performed with 
similar parameters. We specified a precursor mass tolerance of 20 ppm for both engines, and 
a product ion mass tolerance of 20 ppm for X!Tandem and 0.03 Da for Comet. We set a 
maximum of 2 missed cleavages and allowed semi-tryptic peptides. We specified a fixed 
modification of carbamidomethyl on C, and variable modifications for oxidation on M, 
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acetylated protein n termini, and pyro-glu on Q and E. These search parameters are typical 
of those used for PeptideAtlas processing. Others may choose to search without missed 
cleavages, or to search for tryptic peptides only, which would substantially decrease the 
search time. However, we find ~10% of our identifications correspond to semi-tryptic 
peptides, and a greater number to missed cleavages (counting consecutive lysines and 
arginines as potential missed cleavages), so these settings seem worthwhile for a thorough 
analysis.
The search results were then processed with the Trans-Proteomic Pipeline (TPP)26, 27 
version 4.8.1 (Philae) tools. The pepXML26 output for Comet was used directly, and the 
TPP tool Tandem2XML was used to convert the native X!Tandem output to pepXML. The 
set of pepXML files from each engine was processed together with PeptideProphet28 with 
the default parameters with the addition of enabling the accurate mass model. The two 
output files from the PeptideProphet analysis of the X!Tandem results and the Comet results 
were then processed together by iProphet29 to refine the statistical models from 
PeptideProphet using additional corroborating information from other identifications.
Results
The databases
The listing of the four derived search databases presented in this work is shown in Table 4, 
along with inherent attributes and end processing results for each database. The number of 
distinct protein accessions in each database is a simple count of entries, and the number of 
distinct proteins is the number of entries where sequence-exact duplicates are only counted 
once. The number of distinct peptide sequences is a tally of all distinct peptides between 7 
and 50 amino acids inclusive after in silico digestion with trypsin with no missed cleavages 
(in contrast to the two missed cleavages used for searching); peptides that are otherwise 
identical except for an I/L substitution are only counted once. The next column provides the 
mean search time for individual MS runs (using Comet) relative to Tier 1, which with 
~20,000 target sequences and ~20,000 decoy sequences searches quite fast, on average 25 
minutes per file for the HeLa dataset and 10 minutes for the liver dataset with our settings.
Figure 1 depicts the relative sizes of the Tiers 1–4 database in terms of both protein entries 
and distinct peptides. Although Tier 2 is over twice the size of Tier 1 in terms of protein 
entries, Tier 2 is only marginally larger in terms of distinct peptide because it is primarily 
alternative splice isoforms of proteins in Tier 1.
Comparison of search results at the peptide level
The results of searching the test datasets against the four tiered databases and post-
processing the search results with the TPP as described in the methods are presented in 
Table 4 for the HeLa dataset and Table 5 for the liver dataset. The first few columns describe 
the database searched, as already presented above. Column 5 provides the relative search 
time for the different databases as compared to Tier 1. Tiers 2, 3, and 4 are approximately 2, 
4, and 8 times as computationally expensive to search as Tier 1, respectively, due to their 
increasing size.
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Column 6 lists the total number of distinct peptides that pass the selected thresholds. 
Although the sizes of the databases vary by a factor of 10, each of the searches yielded 
nearly the same number of distinct peptides (~101,000 for the HeLa dataset 1 and ~42,000 
for the normal liver dataset 2) after TPP processing and thresholding at a consistent FDR. 
These total numbers of identifications do not vary substantially with database size, 
suggesting that the larger databases do not degrade the sensitivity of the searches.
The incremental results at the peptide level are presented in the last four columns of Tables 4 
and 5 as well as Figure 2. Column 7 lists the number of decoys in the set of distinct observed 
peptides. The thresholds were selected at a level that provided a consistent number of decoys 
for each of the four searches. The selected peptide-level FDR thresholds were set to 
approximately 0.0002 for both the HeLa sample dataset and the liver sample dataset, 
calculated based on decoy counts. The number of decoys present in each filtered list is 
shown. Column 8 lists the number of new distinct peptides detected above the selected 
threshold that were not present in previous databases, i.e. the number of distinct peptides 
sequences present in a search result that could not have been present in an earlier result 
because they were not in the search database. New peptides that pass the threshold but were 
present in an earlier database are not counted, as these are likely just artifacts of the 
thresholding process. These novel distinct peptides are tentative findings, pending specific 
assessment of likely matches to known peptides and proteins with amino acid substitutions 
or isobaric PTMs, in accord with the HPP Guidelines13. Column 9 provides the numbers of 
non-redundant protein entries that have at least one uniquely mapping peptide to them. Each 
of the decoy peptide entries in column 7 map to a distinct protein, and therefore the protein-
level FDR is ~0.003.
Again for reference, the number of decoys present in the novel list is shown. Finally, the last 
column provides the cumulative number of these novel peptides. The numbers of detected 
novel peptides are many times greater than the numbers of decoys. Adding the varsplic 
portion of UniProtKB to the canonical ~20,000 Swiss-Prot yielded only 721 new distinct 
peptides not present in the smaller database in the HeLa search. Note that the increment in 
the total number of distinct peptides from Tier 1 to Tier 2 is different than this merely due to 
slight artifacts in the modeling that allows us to set an FDR threshold. If we then augment 
the search database to include the UniProtKB Complete Proteome and other sequences, an 
additional 379 new distinct peptides that are not present in previous databases are identified. 
Finally, when we then search with the Tier 4 database, which contains a very large number 
of potential sequences from UniProt/TrEMBL and RefSeq, we identify an additional 324 
distinct peptides in the HeLa dataset corresponding to sequence that was not present in 
lesser databases. We note that all tiers include the cRAP contaminant database as we feel 
that it is always important to include these in any search; a total of 7 contaminant proteins, 
including porcine trypsin, bovine albumin, and sheep keratins were identified in these 
datasets.
Origin of the novel peptides
Increasing the completeness of the sequence databases clearly yields a small but measurable 
increase in the number of identified peptides. In Figure 3, we show the basic categories of 
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peptides that are newly identified in the expanded databases. We consider only peptides that 
could not be identified in the smaller database because they were not present there. Any 
peptides that were present in the smaller database, but were not above threshold in the search 
against that database, yet were present in the search against the larger database, are assumed 
to be an artifact of the thresholding process (i.e. just barely did not pass in the smaller 
database search, but now do pass in the larger database with the new error model) and are 
not of interest.
In the transition from the Tier 1 to Tier 2 database, our two test datasets yield a 0.7% to 
0.85% increase in distinct peptides from isoforms and immunoglobulins. The 
immunoglobulins are seen only in the tissue sample dataset, contributing to over half of the 
new identifications. In the transition from the Tier 2 to Tier 3 database, our two test datasets 
yield a further 0.2% to 0.4% increase in novel peptides, mostly from UniProtKB/TrEMBL 
sequences that are part of the “complete proteome” set but not part of neXtProt. Finally, in 
the transition from the Tier 3 to Tier 4 database, our two test datasets yield a further 0.3% to 
0.5% increase in novel peptides, mostly from UniProtKB/TrEMBL and RefSeq entries. 
Novel peptides that map to both resources, of which there are very few, are arbitrarily 
assigned to UniProtKB/TrEMBL in this figure. The full list of peptides, their categories, and 
hyperlinks to the PeptideAtlas web site are available in the supplementary material as 
Supplementary Table 1.
Using the PeptideAtlas Mapping database to verify unique peptides
Although one may use one of the lower-tier search databases to avoid the negative impacts 
of the larger databases, the PeptideAtlas mapping database is still useful to ensure that 
peptides that appear to be uniquely mapping in smaller databases do not in fact also have 
alternate mappings to other proteins when a larger reference proteome that includes SAAVs 
is considered. This is especially important when considering peptides as sole evidence for 
the detection of HPP “missing proteins” (neXtProt PE2-4) or neXtProt “dubious proteins” 
(PE5)11 (often a predicted sequence strongly suspected, yet with some remaining doubt, to 
correspond to a pseudogene).
As an example, we take all 100,824 distinct peptides identified in the search of the HeLa 
cell-line data against the Tier 1 database. We filter this to retain only the uniquely mapping 
peptides within that database to obtain 96,093. We then remap this set of 96,093 uniquely 
mapping peptides to the PeptideAtlas mapping database (PAmap in Table 3), and retain just 
those peptides that now map to a different neXtProt entry as an isoform or a SAAV. The 
result is that there are 82 peptides that map to only one neXtProt entry in a Tier 1 search, but 
then also map to at least one other neXtProt entry when isoforms and SAAVs are considered. 
This demonstrates that, even when a database with many expanded SAAVs is detrimental to 
database searching, it still may be a useful mapping database to verify that apparently 
uniquely mapping peptides are still correct when all known variants are considered. We note 
that Nesvizhskii suggests that before claiming discoveries of novel translation products, 
several reference databases need to be examined to ensure that the apparent novel finding is 
not just a curation problem in one database30; we suggest that the Tier 4 and the 
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PeptideAtlas mapping databases are sufficiently complete integrated databases that it is the 
only one that needs to be checked.
Distribution and Identifiers of Releases
In addition to individual files available via FTP, we support the new BDBag format and 
minid identifiers (Chard et al., in preparation) for each release. This facilitates the 
automation of download and validation of the released files, as well as unique identification 
of the files with globally unique and trackable identifiers. All of the main release files, Tiers 
1–4, both as target alone and target + decoys, are packaged into a BDBag, which contains an 
internal manifest and checksums. All of the individual components, which may be used to 
create custom combinations, are packaged into a separate BDBag. These two BDBags are 
given unique minid identifiers, which may be referenced in a manuscript or entered into 
software that is capable of resolving and handling BDBags and minids. See Chard et al. or 
http://ini-bdds.github.io/ for more information on how to use these tools.
Conclusion
We have developed a set of tiered, increasingly complete human protein sequence databases 
suitable for mass spectrometry proteomics sequence database searching, called the Tiered 
Human Integrated Search Proteome (THISP) set, based primarily on the neXtProt 
knowledge base, the primary knowledge base for the Human Proteome Project, 
supplemented with many other non-redundant sequences from several other human 
reference proteomes. We have explored the performance when searching with these various 
sequence databases to understand the relative increase in the number of distinct peptide 
identifications along with the increased computational cost of using larger databases. The 
number of increased identifications is rather small compared to the additional computational 
cost, but the additional cost may be worth bearing if the identification of sequence variants 
or the discovery of sequences that are not present in the reviewed knowledge base entries is 
an important goal of the study. In order to maintain the freshness and availability of this 
resource, we have set up a fully automated process to regenerate these databases on the first 
of every month, available for free download at http://www.peptideatlas.org/thisp/. Additional 
information and any future changes to the build process will be made available at the same 
web site. We intend that the availability of this resource will make it easier to HUPO HPP 
research efforts to comply with the HPP Mass Spectrometry Data Interpretation 
Guidelines13.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Representation of the relative sizes of the 4 tiers of database size based on the number of 
protein entries (left) and the number of distinct tryptic peptides (right). The rectangle areas 
are proportional to the number of counted items, scaled to the size of Tier 4. The quantities 
represented are written in the upper-right corner of each rectangle, in thousands (k).
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Figure 2. 
Comparison of the cumulative increase in percentage of identified novel distinct peptides 
that were not present in the Tier 1 database versus the relative search time over the Tier 1 
search. The data points are in order left to right for the Tier 1 (at 1,0), Tier 2, Tier 3, and Tier 
4 searches, respectively, for both the HeLa cell dataset and the liver tissue dataset.
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Figure 3. 
Comparison of additional peptides identified when searching progressively higher THISP 
Tiers 2, 3, and 4. The heights of the stacked bars are presented as the percentage of 
additional peptides identified. Within each of the three clusters, we show results for the two 
test datasets, liver tissue and HeLa cells. The first cluster represents the additional peptides 
gained when moving from the Tier 1 database to the Tier 2 database; the second cluster 
represents Tier 2 to Tier 3; the third cluster from Tier 3 to Tier 4. The colors of the stacks 
represent five major categories of novel peptides (i.e. new peptides identified via the higher 
tier that could not have been identified in the lower tier): immunoglobulins (Igs) in purple, 
known neXtProt splice isoforms in dark blue, RefSeq in green, UniProtKB/TrEMBL 
sequences in orange, and other sequences (such as contributed sequences, etc.) in light blue. 
The 0.02% peptide-level decoy rate (and presumed FDR) is depicted in red.
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Table 2
Short tags and longer descriptions of all sequence components that are combined to create the various 
complexity tiers of the generated human search databases.
Tag Description
nP20k neXtProt ~20,000 canonical sequences
nPvarsplic neXtProt ~22,000+ “varsplic” splice isoforms
SPnotnP UniProtKB/Swiss-Prot sequences not in neXtProt, primarily Ig proteins
Nh-cRAP Non-human contaminant proteins from GPM
UPCP UniProtKB “complete proteome” set
UPTr UniProtKB/TrEMBL sequences not in “complete proteome” set
IMGT IMmunoGeneTics variable region sequences
Microbe Microbial proteins from Zubarev et al. supplemented with additional potential contaminants
IPIorphan Small set of IPI protein entries that seems to have identified novel peptides in PeptideAtlas
Contribs Set of potential protein sequences contributed by human genome curators or others to be on the PeptideAtlas watch list
RSDiffNP RefSeq NP (reviewed) sequences not found in UniProtKB
RSDiffXP RefSeq XP (unreviewed) sequences not found in UniProtKB
RefSeq All of the NCBI RefSeq NP and XP sequences
Ensembl All of the Ensembl sequences
SAAVnPnotCOS neXtProt sequences appended with all SAAVs listed in neXtProt except for the COSMIC-only set
SAAVnPall neXtProt sequences appended with all SAAVs listed in neXtProt
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